Home Health Cognitive decline, dementia associated with levodopa-induced dyskinesia in Parkinson's disease

Cognitive decline, dementia associated with levodopa-induced dyskinesia in Parkinson's disease

The study of levodopa-induced dyskinesia (LID) seems to correlate with cognitive decline, as well as with the development of Parkinson's dementia (PD), the researchers found. The results of this study have been published in Neurology.

A total of 119 patients with PD who were treated with levodopa for more than 5 years were included in this retrospective cohort study. All patients underwent neuropsychological and cerebral MRI at baseline and follow-up N– (3-[[[[18F]fluoropropyl) -2β-carbomethoxy-3β- (4-iodophenyl) nortropane (18F-FP-CIT) positron emission tomography examinations. Patients were classified as LID (PD-LID +; n = 38) or not with LID (PD-LID-; n = 81). In an analysis adjusted for age, sex, years of education, body mass index, baseline motor severity and levodopa increase at year, researchers compared rates of cognitive decline using a mixed linear model and dementia conversion between PD-LID + and PD -LID- groups.

There was no difference between the 2 groups at baseline with regard to neuropsychological performance or the percentage of patients with mild cognitive impairment. Patients in the PD-LID + group presented significantly faster frontal executive function decreases than in the PD-LID- group (-0.149; P = .002). Furthermore, the PD-LID + group had significantly faster decrements in global cognitive function (-0.090; P = .033) and Mini-Mental State Examination total score (-0.351; P = .012).

Furthermore, patients in the PD-LID + group had a higher conversion rate to dementia than those in the PD-LID group (adjusted risk ratio [aHR], 3.94; 95% CI, 1.76-8.82; P = .010). The PD-LID + group also demonstrated a risk of conversion of higher PD dementia if it had mild cognitive impairment compared to those in the PD-LID group with normal cognition (aHR, 6.08, 95% CI, 1.25-29.56) mild cognitive impairment (aHR 4.05; 95% CI, 1.14-14.43).

The limits of the study include the high exclusion rate and the retrospective nature of the analysis.

The results of this study "give us a new perspective in the study of the pathophysiology of LID and cognitive decline in PD and the contributions of chronic dopaminergic stimulation to plasticity to cognition", the researchers concluded.

Reference

Yoo HS, Chung SJ, Lee YH, et al. Levodopa-induced dyskinesia is closely linked to the progression of frontal dysfunction in PD [published online February 22, 2019]. Neurology. doi: 10.1212 / WNL.0000000000007189.

Must Read

Senate Race 2020: Here's what happened

Republicans have a better goal than Senate control in 2020. However, recent trends suggest that the possibility of a clean turnaround for both sides...

Dosimetry Equipment Market 2019 Key players: Thermo Fisher Scientific, Panasonic, Fuji Electric, Landauer, Hitachi, Polimaster, Ludlum Measurements, Mirion Technologies

Dosimetry The "Dosimetry Equipment Market" report covers market share, dimensions, CAGR, industry analysis, market strategy, statistical analysis, sales, revenue, key players, product and...

new PS5 streaming service for joining games and movies

Sony could unite two of its greatest strengths: games and movies, to reinforce the road map of PlayStation 5 services. Services are...

Terror in Sri Lanka: The fear is back

Sri Lanka awakens after Easter, when the terror has returned. All the dead lying in the police morgue, all the traumatized wounded being treated...

Market survey for flip-flop market data 2013-2025 Market trends, technology, applications and segment forecasts until 2023

Flip-flops market data The Market Data Collection Report for Flip-Flops 2013-2025 The market has grown steadily in recent years and is expected to...